Spyre Therapeutics, Inc.
DE ˙ DB ˙ US00773J2024
63,00 € ↑3,00 (5,00%)
2026-06-04
DEL PRIS
SecurityDE:3920 / Spyre Therapeutics, Inc.
InstitutionStemPoint Capital LP
Latest Disclosed Ownership167,606 shares
Latest Disclosed Value $ 8,454,047
StemPoint Capital LP reports 417.67% increase in ownership of 3920 / Spyre Therapeutics, Inc.

On May 18, 2026 - StemPoint Capital LP filed a 13F-HR/A form disclosing ownership of 167,606 shares of Spyre Therapeutics, Inc. (DE:3920) valued at $6,637,198 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 32,377 shares of Spyre Therapeutics, Inc.. This represents a change in shares of 417.67% during the quarter. The current value of the position is $10,559,178 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-18 2026-03-31 13F/A-1 SPYRE THERAPEUTICS COM NEW 00773J202 167,606 135,229 417.67 8,454 697.55 1.6000
2026-05-15 2026-03-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 167,606 135,229 8,454 1.6418
2026-02-17 2025-12-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 32,377 32,377 1,061 0.1819
2025-08-14 2025-06-30 13F SPYRE THERAPEUTICS COM NEW 00773J202 0 -136,139 -100.00 0 -100.00
2025-05-15 2025-03-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 136,139 136,139 2,197 0.7002
2024-11-13 2024-09-30 13F SPYRE THERAPEUTICS COM NEW 00773J202 0 -150,450 -100.00 0 -100.00
2024-08-13 2024-06-30 13F/A-1 SPYRE THERAPEUTICS COM NEW 00773J202 150,450 88,197 141.68 3,537 49.81 1.0395
2024-08-13 2024-06-30 13F SPYRE THERAPEUTICS COM NEW 00773J202 150,450 88,197 3,537 1.0347
2024-08-09 2024-03-31 13F/A-1 SPYRE THERAPEUTICS COM NEW 00773J202 62,253 -316,513 -83.56 2,361 -71.03 0.6241
2024-05-14 2024-03-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 62,253 -316,513 2,361 0.6196
2024-02-13 2023-12-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 378,766 378,766 8,151 2.1746
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.